Home › Multiple Sclerosis › California
Multiple Sclerosis clinical trials in California
24 studies for Multiple Sclerosis are looking for participants at sites in California.
Cities in California
Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO
- University of California Davis Comprehensive Cancer Center, Sacramento
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 23, 2026 · NCT03816345A Study Evaluating the Real World Experience of Participants Treated With BRIUMVI® (Ublituximab-xiiy) for Relapsing Multiple Sclerosis (RMS)
- TG Therapeutics Investigational Trial Site, Fresno
- TG Therapeutics Investigational Trial Site, Newport Beach
- TG Therapeutics Investigational Trial Site, Orange
- and 1 more
RecruitingObservational study
Ages 18 and older · All sexes · Updated Sep 23, 2026 · NCT06433752Treatment of Participants With Primary or Secondary Progressive Multiple Sclerosis
- UC San Diego, La Jolla
RecruitingPhase 1/2
Ages 18 to 65 · All sexes · Updated Sep 21, 2026 · NCT07477639Non-inferiority Study of Frexalimab Subcutaneous Administration Compared to Intravenous Administration in Adult Participants With Multiple Sclerosis
- Private Practice - Dr. Regina Berkovich- Site Number : 8400005, West Hollywood
RecruitingPhase 3
Ages 18 to 60 · All sexes · Updated Sep 15, 2026 · NCT07325292RE104 Safety and Efficacy Study in Adjustment Disorder in Cancer and Other Medical Illnesses
- Kadima Neuropsychiatry Institute, San Diego
- Providence Medical Foundation, Santa Rosa
RecruitingPhase 2
Ages 18 to 80 · All sexes · Updated Sep 15, 2026 · NCT07002034Study to Evaluate the Effectiveness and Safety of Ozanimod Compared to Fingolimod in Children and Adolescents With Relapsing Remitting Multiple Sclerosis
- Local Institution - 0114, Loma Linda
- University of California Davis Health, Sacramento
RecruitingPhase 3
Ages 10 to 17 · All sexes · Updated Sep 10, 2026 · NCT06408259A Study to Assess the Safety and Clinical Activity of Azer-cel in Participants With B-cell Mediated Autoimmune Disorders
- TG Therapeutics Investigational Trial Site, La Jolla
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 9, 2026 · NCT06680037A Study Evaluating the Safety and Efficacy of KITE-363 in Relapsed/Refractory Autoimmune Neurologic Diseases
- Hoag Memorial Hospital Presbyterian, Newport Beach
- Stanford Neuroscience Health Center, Palo Alto
RecruitingPhase 1
Ages 18 to 75 · All sexes · Updated Aug 14, 2026 · NCT07304154Pregnancy Registry, Infants, Serum/Milk Analysis (PRISMA)
- University of California-San Francisco, San Francisco
RecruitingObservational studyHealthy volunteers welcome
Ages 18 to 64 · Women · Updated Aug 11, 2026 · NCT06940323A Study to Evaluate the Efficacy and Safety of Remibrutinib in Secondary Progressive Multiple Sclerosis
- Fullerton Neuro and Headache Ctr, Fullerton
- Regina Berkovich MD PhD Inc, West Hollywood
RecruitingPhase 3
Ages 18 to 65 · All sexes · Updated Jul 29, 2026 · NCT07225504Assessing Changes in Multi-parametric MRI in MS Patients Taking Clemastine Fumarate as a Myelin Repair Therapy
- Sandler Neurosciences Building, Neurological Clinical Research Unit, San Francisco
RecruitingPhase 1/2
Ages 18 to 55 · All sexes · Updated Jul 2, 2026 · NCT05359653Hyperpolarized Carbon Metabolic Imaging in Multiple Sclerosis
- Byers Hall, San Francisco
RecruitingPhase 2Healthy volunteers welcome
Ages 18 and older · All sexes · Updated Jun 8, 2026 · NCT07510607ECoG BMI for Motor and Speech Control
- University of California San Francisco, San Francisco
Recruiting
Ages 21 and older · All sexes · Updated May 5, 2026 · NCT03698149Care in Multiple Sclerosis (MS)
- University of California, San Francisco, San Francisco
RecruitingObservational study
Ages 18 and older · All sexes · Updated May 5, 2026 · NCT07011914Obe-cel in Refractory Progressive Forms of Multiple Sclerosis
- Stanford University, Redwood City
RecruitingPhase 1
Ages 18 to 60 · All sexes · Updated Mar 23, 2026 · NCT07139743Assessment of Clemastine Fumarate as a Remyelinating Agent in Acute Optic Neuritis (ReCOVER)
- University of California San Francisco, San Francisco
RecruitingPhase 2
Ages 18 to 55 · All sexes · Updated Mar 11, 2026 · NCT02521311A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell ( CAR-T) Therapy in Subjects With Non-relapsing and Progressive Forms of Multiple Sclerosis
- Stanford Multiple Sclerosis Center, Palo Alto
RecruitingPhase 1
Ages 18 to 65 · All sexes · Updated Feb 27, 2026 · NCT06138132Central Vein Sign in Multiple Sclerosis Extension Study
- Cedars-Sinai Medical Center, Los Angeles
Recruiting
Ages 18 to 65 · All sexes · Updated Feb 20, 2026 · NCT07424027"Selfie" Videos: A Novel, Patient-centered, Comprehensive Approach to Measuring Function in MS
- University of California, San Francisco, San Francisco
RecruitingObservational study
Ages 18 and older · All sexes · Updated Oct 31, 2025 · NCT07222618Safety, PK and Biodistribution of 18F-OP-801 in Patients With ALS, AD, MS, PD and Healthy Volunteers
- UCSF, San Francisco
- Stanford University, Stanford
RecruitingPhase 1/2Healthy volunteers welcome
Ages 18 to 80 · All sexes · Updated May 2, 2025 · NCT05395624Kesimpta (Ofatumumab) Pregnancy Registry
- University of California San Diego OTIS, La Jolla
RecruitingObservational studyHealthy volunteers welcome
Ages 18 to 100 · All sexes · Updated Jan 14, 2025 · NCT05634967Entire-body PET Scans for Multiple Sclerosis
- Brain Health Alliance, Ladera Ranch
RecruitingEarly phase 1Healthy volunteers welcome
Ages 25 to 55 · All sexes · Updated Jan 7, 2025 · NCT04390009Post-Authorization Safety Study for Assessment of Pregnancy Outcomes in Patients Treated With Mayzent
- Novartis Investigative Site, La Jolla
RecruitingObservational studyHealthy volunteers welcome
All ages · Women · Updated May 16, 2024 · NCT04933552MS-ResearchBiomarkerS
- Cedars-Sinai Medical Center, Los Angeles
RecruitingObservational studyHealthy volunteers welcomeMentions payment for participants
Ages 18 and older · All sexes · Updated Feb 6, 2024 · NCT05204459From ClinicalTrials.gov, data retrieved Sep 29, 2026. Each study sets its own eligibility; the study team decides who can join.